TEL AVIV, Israel–(BUSINESS WIRE)–Azura Ophthalmics Ltd. announced multiple presentations highlighting positive efficacy and safety data from Phase 2 studies of AZR-MD-001.
Author: Business Wire
Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the cli…
Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering
BEDFORD, Mass.–(BUSINESS WIRE)–Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the pricing o…
Wiregrass Museum of Art to Loan EnChroma Glasses to Color Blind Visitors
DOTHAN, Ala. & BERKELEY, Calif.–(BUSINESS WIRE)– #enchroma–Wiregrass Museum of Art (WMA) and EnChroma® – creators of glasses for color blindness – today announced that WMA will loan EnChroma glasses to visitors who are red-green color blind so they …
Bausch + Lomb Will Present New Scientific Data and Analyses at the American Society of Cataract and Refractive Surgery Annual Meeting
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced fifteen podium and four poster presentations during the American S…
Center For Sight Implants New FDA-Approved iDose®TR Device
SARASOTA, Fla.–(BUSINESS WIRE)– #Eyecare–Center For Sight, A US Eye Company, one of the nation’s leading ophthalmology practices, has performed the first iDoseTR implant surgery in the state of Florida since the device was approved by the Food and D…
Stoke Therapeutics Announces Proposed Public Offering
BEDFORD, Mass.–(BUSINESS WIRE)–Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced a proposed un…
NovaBay Pharmaceuticals Reports 2023 Fourth Quarter and Full Year Financial Results
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three and 12 months ended December 31, 2023 and provides a business update. “Quarterly revenue from our eyecare and wound care se…
NovaBay Pharmaceuticals to Hold 2023 Fourth Quarter and Full Year Conference Call on March 26, 2024
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three and 12 months ended December 31, 2023 after market close on Tuesday, March 26, 2024 and will hold an …
MyEyeDr. Partners with Prevent Blindness to Promote Eye Health and Safety During April 8 Solar Eclipse, Gives Away Solar Glasses at 400+ Locations
VIENNA, Va.–(BUSINESS WIRE)–Ahead of the total solar eclipse on Monday, April 8, MyEyeDr., a leading provider of eye health services with over 800 locations across the U.S., is educating consumers about the importance of eye health and the need for p…
Translational Vision Science and Technology Journal Publishes RadiusXR's NOVA Clinical Trial, Demonstrating Industry-Leading Accuracy and Innovation in Visual Field Testing for Virtual Reality Perimetry
PLEASANTON, Calif.–(BUSINESS WIRE)– #Ophthalmology–RadiusXR, the trailblazer in Digital Health, announces the publication of its groundbreaking NOVA Clinical Trial in Translational Vision Science and Technology (TVST), a prestigious journal by the A…
Horus Pharma Renews Its Partnership With Plastic Bank
NICE, France–(BUSINESS WIRE)–Horus Pharma, an independent French laboratory specialised in ophthalmology known for its expertise in developing preservative-free products designed to facilitate eye and eyelid health, has extended its successful collab…
GenSight Biologics Reports Full Year 2023 Consolidated Financial Results
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and cent…
LENZ Therapeutics Announces Completion of Merger with Graphite Bio and Provides Update on Recent Clinical and Corporate Progress
SAN DIEGO–(BUSINESS WIRE)–LENZ Therapeutics, Inc. (Nasdaq: LENZ) (LENZ or the Company), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop that has been shown to improve near vision in people wit…
Senior Ophthalmology Executive Thomas A. (Tom) Dunlap Joins WaveFront Dynamics Inc. as an Independent Member of the Board of Directors to Support the Company’s Ongoing Commercialization and Broader Strategic Initiatives
ALBUQUERQUE, N.M.–(BUSINESS WIRE)–WaveFront Dynamics Inc., a pioneer in wavefront sensing technology perfecting visual performance, welcomes Tom Dunlap to the Board of Directors.
GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ® Injections Four Years After One-Time Administration
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and cent…
GenSight Biologics confirme l’efficacité et la sécurité durables des injections bilatérales de LUMEVOQ® quatre ans après une administration unique
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, éligible au PEA-PME), une société biopharmaceutique spécialisée dans le développement et la commercialisation de thérapies géniques innovantes pour les …
Tilak Healthcare Strengthens Its Leadership Team
PARIS–(BUSINESS WIRE)–Tilak Healthcare, a leading company in digital health for the monitoring of chronic eye diseases, announces the appointment of three experts to support the leadership team, currently composed of Edouard Gasser (CEO & co-foun…
STAAR Surgical Celebrates Three Million Implantable Collamer® Lenses
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that more t…
Nordic Group B.V., par l’intermédiaire de sa filiale Nordic Pharma, Inc. (U.S.), nomme un chirurgien oculoplastique de renom, John P. Fezza, MD, au sein de son conseil consultatif médical
BERWYN, Pennsylvanie–(BUSINESS WIRE)–Nordic Pharma, Inc., une filiale de Nordic Group B.V., annonce aujourd’hui que l’éminent chirurgien oculoplastique John P. Fezza, MD, intégrera son conseil consultatif médical (MAB) aux États-Unis, qui comprend Er…